2-Thiazolamine, 4-(trifluoromethyl)- → 6-{(E)-2-[2-(Cyclobutylmethoxy)-3-(difluoromethoxy)phenyl]vinyl}-N-[4-(trifluoro-methyl)-1,3-thiazol-2-yl]imidazo[2,1-b][1,3]thiazole-5-carboxamide

Participants

Reaction Steps

The title compound was prepared according to the general procedure (Method B) by coupling Intermediate 10 (300 mg, 0.714 mmol) with 4-(trifluoromethyl)-1,3-thiazol-2-amine (128 mg, 0.785 mmol) in the presence of EDCI hydrochloride (273 mg, 1.428 mmol), DMAP (80 mg, 0.714 mmol) in a mixture of THF and DMF (1:1, 6 mL) to give 27 mg of the product as an off-white solid; 1H NMR (300 MHz, CDCl3) δ 1.80-1.90 (m, 4H), 1.98-2.08 (m, 2H), 2.66-2.76 (m, 1H), 3.89-3.95 (m, 2H), 7.15-7.25 (m, 3H), 7.40-7.47 (m, 1H), 7.52-7.67 (m, 2H), 7.78 (d, J=15.9 Hz, 1H), 8.00-8.10 (m, 2H), 13.03 (br s, 1H); APCI-MS (m/z) 571.18 (MH)+.

Provenance & Evidence